s6y

Dermata Therapeutics, Inc.

Ticker
DRMA
CIK
1853816
Industry
Pharmaceutical Preparations
Formerly
Dermata Therapeutics, Inc.

Financials 23

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 23 financials filings

News 80

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 80 news filings

Ownership 111

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 111 ownership filings

Prospectus 56

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. S-3 Registration statement for specified transactions by certain issuers
  3. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  4. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  5. S-3/A Registration statement for specified transactions by certain issuers
  6. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  7. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  8. S-3 Registration statement for specified transactions by certain issuers
  9. S-3 Registration statement for specified transactions by certain issuers
  10. 424B5 Prospectus filed pursuant to Rule 424(b)(5)

All 56 prospectus filings

Proxies 19

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  4. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  5. DEF 14A Definitive proxy statements
  6. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  7. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  8. DEF 14A Definitive proxy statements
  9. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  10. DEF 14A Definitive proxy statements

All 19 proxies filings

Other 85

  1. SCHEDULE 13G
  2. EFFECT Notice of Effectiveness
  3. 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
  4. SCHEDULE 13D
  5. EFFECT Notice of Effectiveness
  6. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  7. SCHEDULE 13G/A
  8. SCHEDULE 13G/A
  9. ARS Annual report to security holders
  10. SCHEDULE 13D/A

All 85 other filings